180 Life Sciences Corp logo

ATNF

180 Life Sciences Corp

$1.02

Earnings Summary

Revenue
$0Mn
Net Profits
$1.56Mn
Net Profit Margins
+Inf%
PE Ratio
1.33

Highlights

Revenue:

180 Life Sciences Corp’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, 180 Life Sciences Corp has generated NaN% jump in its revenue since last 3-months.

Net Profits:

180 Life Sciences Corp’s net profit jumped 109.65% since last year same period to $1.56Mn in the Q1 2022. On a quarterly growth basis, 180 Life Sciences Corp has generated 50.91% jump in its net profits since last 3-months.

Net Profit Margins:

180 Life Sciences Corp’s net profit margin jumped NaN% since last year same period to +Inf% in the Q1 2022. On a quarterly growth basis, 180 Life Sciences Corp has generated NaN% jump in its net profit margins since last 3-months.

PE Ratio:

180 Life Sciences Corp’s price-to-earnings ratio after this Q1 2022 earnings stands at 1.33.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the 180 Life Sciences Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.13
EPS Estimate Current Year
-0.13

Highlights

EPS Estimate Current Quarter:

180 Life Sciences Corp’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

180 Life Sciences Corp’s earning per share (EPS) estimates for the current year stand at -0.13.

Key Ratios

Key ratios of the 180 Life Sciences Corp post its Q1 2022 earnings

Earning Per Share (EPS)
0.05
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
1.05
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

180 Life Sciences Corp’s earning per share (EPS) jumped 106.67% since last year same period to 0.05 in the Q1 2022. This indicates that the 180 Life Sciences Corp has generated 106.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. 180 Life Sciences Corp’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. 180 Life Sciences Corp’s return on equity (ROE) stands at 1.05.

Dividend Per Share (DPS):

180 Life Sciences Corp declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.13
0.05
138.46%

Company Information

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world's biggest drivers of disease - inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company's primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.

Organisation
180 Life Sciences Corp
Employees
2
Industry
Finance